14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
VS vs VRAX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
VRAX Captures Overall Composite Edge (46.5 HOLD vs 40.6 SELL), While VS Leads 3–1 on Growth & Valuation Pillars
VRAX Overall Winner
6-Pillar Tally: VS 3 – 1 VRAX (2 Tie)
Matrix Metrics: VS 3 – 4 VRAX
As of Nov 20, 2026, Virax Biolabs Group Limited (VRAX) captures the overall head-to-head institutional edge over Versus Systems Inc. (VS) on higher Unified Composite conviction (46.5/100 HOLD vs. 40.6/100 SELL) after splitting the core matrix 4–3 (led by Growth & Scale), while VS wins 3–1 across the 6-pillar growth and valuation breakdown. VS trades at $0.57 (N/M Forward P/E, -136.2% operating margin) versus VRAX at $0.33 (N/M Forward P/E, -51515.2% operating margin).
Growth vs. Quality Trade-Off: VRAX earns the overall head-to-head edge with a stronger Unified Composite Score (46.5/100 HOLD vs. VS 40.6/100 SELL) and -8.20β · 162% Vol risk profile, whereas VS leads top-line expansion (-24.7% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: VS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 23.7); meanwhile VRAX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 17.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VS vs VRAX. Trailing 12-month operating profitability (VS -136.2% vs VRAX -51515.2%) and valuation multiples (VS N/M vs VRAX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $470,745 market capitalization and -51515.2% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ VS vs VRAX Key Questions & Quantitative Answers
As of Nov 20, 2026, Virax Biolabs Group Limited (VRAX) captures the overall head-to-head institutional edge over Versus Systems Inc. (VS) on higher Unified Composite conviction (46.5/100 HOLD vs. 40.6/100 SELL) after splitting the core matrix 4–3 (led by Growth & Scale), while VS wins 3–1 across the 6-pillar growth and valuation breakdown. VS trades at $0.57 (N/M Forward P/E, -136.2% operating margin) versus VRAX at $0.33 (N/M Forward P/E, -51515.2% operating margin). Growth vs. Quality Trade-Off: VRAX earns the overall head-to-head edge with a stronger Unified Composite Score (46.5/100 HOLD vs. VS 40.6/100 SELL) and -8.20β · 162% Vol risk profile, whereas VS leads top-line expansion (-24.7% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: VS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 23.7); meanwhile VRAX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 17.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
VRAX leads the Growth & Scale pillar: VS posts -24.7% YoY revenue growth and -30.4% YoY earnings growth on $1.5M TTM revenue (100.0% gross margin, -136.2% operating margin), compared with VRAX at +684.9% YoY revenue growth and +0.0% YoY earnings growth on $12,423 TTM revenue (61.9% gross margin, -51515.2% operating margin). On trailing 12-month operating scale, VS generates $1.5M in USD-normalized revenue versus $12,423 for VRAX. In operating R&D and SG&A reinvestment, VS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VRAX.
VS screens cheaper on headline valuation multiples. VS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.8x EV/Revenue (unreported FCF margin), whereas VRAX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 37.9x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VS (-69.2% ROE) versus VRAX (-78.6% ROE) capital efficiency.
In options market volatility and institutional positioning, VS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.45β · 78% Vol realized risk). By comparison, VRAX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-8.20β · 162% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.